FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 programnews2025-11-25T15:50:45+00:00November 25th, 2025|Endpoints News|
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis datanews2025-11-24T15:39:54+00:00November 24th, 2025|Endpoints News|
Sarepta ends Elevidys trial with Hansa’s pre-treatment; Some pipeline cuts at Modernanews2025-11-21T16:12:27+00:00November 21st, 2025|Endpoints News|
Abbott’s $21B diagnostic deal; Job cuts at Applied Therapeutics and AbbVienews2025-11-20T16:38:35+00:00November 20th, 2025|Endpoints News|
Pfizer’s antibody pact with Nona Biosciences; Epkinly’s label expansionnews2025-11-19T14:45:01+00:00November 19th, 2025|Endpoints News|
Merck, Bristol Myers disclose layoffs in New Jerseynews2025-11-18T15:12:17+00:00November 18th, 2025|Endpoints News|
How the Lilly-Adverum deal came together; Captain T Cell reels in €20Mnews2025-11-17T16:10:06+00:00November 17th, 2025|Endpoints News|
Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer programnews2025-11-14T16:06:15+00:00November 14th, 2025|Endpoints News|
MacroGenics stops work on a bispecific; Third Arc Bio makes a deal with Adagenenews2025-11-13T15:56:22+00:00November 13th, 2025|Endpoints News|
Voyager, Transition Bio’s small molecule drug pact; CRISPR Therapeutics ends work on a CAR-T therapynews2025-11-11T15:41:06+00:00November 11th, 2025|Endpoints News|
